Stockscreener 앱 받기
4.3988
6.25%
0.2588
Inmed Pharmaceuticals Inc 주식(INM)의 최신 뉴스
InMed Pharmaceuticals Inc. Holds 2024 Annual General Meeting – Elects Directors and Appoints Auditor - Defense World
InMed Pharmaceuticals Director Faces Resignation After Shareholder Vote at Annual Meeting - StockTitan
InMed Announces Results of 2024 Annual General Meeting - Newsfile
InMed Pharmaceuticals Inc. announced that it expects to receive CAD 10 million in funding - Marketscreener.com
InMed Enters Into Standby Equity Purchase Agreement - Newsfile
Head-To-Head Review: InMed Pharmaceuticals (NASDAQ:INM) & Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
InMed Pharmaceuticals (TSE:IN) Trading Down 1.6% – Time to Sell? - Defense World
InMed Pharmaceuticals (FRA:MWG) Altman Z-Score : -14.86 (As of Dec. 05, 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) Altman Z-Score : -14.90 (As of Dec. 03, 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) Inventories, Finished Goods : €0.84 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) Shares Outstanding (EOP) : 0.67 Mil (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Total Liabilities : $2.07 Mil (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Debt-to-Equity : 0.13 (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Dividend Yield % : 0.00% (As of Nov. 26, 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Dividend Payout Ratio : 0.00 (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) EBITDA : $-6.66 Mil (TTM As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Cash, Cash Equivalents, Marketa - GuruFocus.com
INM (InMed Pharmaceuticals) Growth Rank : 0 (As of Nov. 26, 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Machinery, Furniture, Equipment : $0.04 Mil (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) 3-Year EPS without NRI Growth R - GuruFocus.com
INM (InMed Pharmaceuticals) Total Inventories : $1.22 Mil (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Net Income : $-6.82 Mil (TTM As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Inventory Turnover : 0.63 (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Revenue per Share : $49.03 (TTM As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Forward Dividend Yield % : 0.00% (As of Nov. 26, 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) 9-Day RSI : 44.83 (As of Nov. 26, 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Price-to-Operating-Cash-Flow : (As of Nov. 26, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Ending Cash Position : €5.03 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) EBITDA : €-6.11 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) Book Value per Share : €11.34 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Accounts Receivable : €0.26 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Pre-Tax Income : €-6.25 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Days Inventory : 147.82 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) GF Score : 43/100 (As of Nov. 21, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Earnings per Share (Diluted) : €-59.16 (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Median PS Value : €0.00 (As of Nov. 21, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Asset Turnover : 0.11 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Net Income From Continuing Operations : €-6.25 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cost of Goods Sold : €3.11 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Intrinsic Value: DCF (Earni - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Free Cash Flow : €-6.08 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) COGS-to-Revenue : 0.61 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cash Flow from Operations : €-6.08 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Earnings Yield (Joel Greenb - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Net-Net Working Capital : €5.86 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Quick Ratio : 4.22 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Debt-to-Revenue : 0.21 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Price-to-Owner-Earnings : (As of Nov. 21, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cash-to-Debt : 5.28 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cyclically Adjusted PB Rati - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cash Flow for Dividends : €0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cyclically Adjusted FCF per Share : €-485.97 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Price-to-Free-Cash-Flow : N/A (As of Nov. 21, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cyclically Adjusted Book pe - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Forward Dividend Yield % : 0.00% (As of Nov. 20, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cyclically Adjusted PS Rati - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Inventories, Finished Goods : €0.84 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 3-Year Book Growth Rate : -64.40% (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Future 3-5Y EPS without NRI Growth Rate : N/A (As of Nov. 20, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Other Current Liabilities : €0.21 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) EPS (Basic) : €-59.16 (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Other Long-Term Liabilities : €0.00 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cash From Discontinued Inve - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Other Long Term Assets : €0.09 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cash Ratio : 3.89 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cash Flow from Investing : €-0.01 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) EBIT : €-6.66 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) Peter Lynch Fair Value : €-1,493.15 (As of Nov. 20, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cash From Other Investing A - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Dividend Payout Ratio : 0.00 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Long-Term Capital Lease Obl - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Total Stockholders Equity : €7.56 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) EV-to-EBITDA : 0.22 (As of Nov. 20, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cyclically Adjusted Revenue per Share : €68.91 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Purchase Of Investment : €-0.04 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Change In Receivables : €-0.11 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 3-Year EPS without NRI Grow - GuruFocus.com
2.88%
2.65%
자본화:
|
볼륨(24시간):